Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

JAMA

Volumn 283, Issue 24, 2000, Pages 3217-3222

  Fowler, Floyd J ^a   McNaughton Collins, Mary ^b   Albertsen, Peter C ^c   Zietman, Anthony ^b   Elliott, Diana B ^a   Barry, Michael J ^b  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; COMPARATIVE STUDY; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0343962219     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.24.3217     Document Type: Article

References (17)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-980.
3. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906-910.
4. D'Amico AV, Whittington R, Malkowicz B, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
5. Moore MJ, O'Sullivan BO, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol. 1988;6:1736-1745.
6. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;277:1445-1451.
7. US Preventive Services Task Force. Screening for prostate cancer: commentary on the recommendations of the Canadian Task Force on the periodic health examination. Am J Prev Med. 1994;10:187-193.
8. American College of Physicians. Screening for prostate cancer: Clinical Guideline, Part III. Ann Intern Med. 1997;126:480-484.
9. Fowler FJ, Barry MJ, Lu-Yao G, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three Surveillance, Epidemiology, and End Results areas. J Clin Oncol. 1996;14:2258-2265.
10. Jonler M, Messing EM, Rhodes RP, et al. Sequelae of radical prostatectomy. Br J Urol. 1994;74: 352-358.
11. Jonler M, Ritter MA, Brinkman R, et al. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology. 1994;44:876-882.
12. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 1997; 89:1117-1123.
13. Stanford J, Feng Z, Hamilton A, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA. 2000;283:354-360.
14. Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
15. Fowler FJ, Bin L, McNaugnton Collins M, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-532.
16. Wilt TJ, Brawer MK. The Prostate cancer Intervention Versus Observation Trial (PIVOT). Oncology. 1997;11:1133-1139.
17. Ontel E, Hamond C, Wasson JH, et al. Assessment of the feasibility and impact of shared decision making in prostate cancer. Urology. 1998;51:63-66.